Abstract
Purpose: This paper provides a review on molecular imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) for prostate cancer detection and its applications in fusion targeted biopsy of the prostate. Methods: Literature search was performed through the PubMed database using the keywords “prostate cancer”, “MRI/ultrasound fusion”, “molecular imaging”, and “targeted biopsy”. Estimates in autopsy studies indicate that 50% of men older than 50 years of age have prostate cancer. Systematic transrectal ultrasound (TRUS) guided prostate biopsy is considered the standard method for prostate cancer detection and has a significant sampling error and a low sensitivity. Molecular imaging technology and new biopsy approaches are emerging to improve the detection of prostate cancer. Results: Molecular imaging with PET and MRI shows promising results in the early detection of prostate cancer. MRI/TRUS fusion targeted biopsy has become a new clinical standard for the diagnosis of prostate cancer. PET molecular image-directed, three-dimensional ultrasound-guided biopsy is a new technology that has great potential for improving prostate cancer detection rate and for distinguishing aggressive prostate cancer from indolent disease. Conclusion: Molecular imaging and fusion targeted biopsy are active research areas in prostate cancer research.
Original language | English (US) |
---|---|
Pages (from-to) | 29-43 |
Number of pages | 15 |
Journal | Clinical and Translational Imaging |
Volume | 5 |
Issue number | 1 |
DOIs | |
State | Published - Feb 1 2017 |
Externally published | Yes |
Keywords
- Image registration
- Image segmentation
- Magnetic resonance imaging (MRI)
- Molecular imaging
- Positron emission tomography (PET)
- Prostate cancer
- Targeted biopsy
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging